NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NEUROCRINE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$136.98+1.27 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
Neurocrine Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Market Cap | $13.92B | $164.85M |
| Enterprise Value | $13.53B | $87.06M |
| PE Ratio | 20.09 | 19.63 |
| PS Ratio | 4.13 | 3.60 |
| PB Ratio | 3.77 | 2.03 |
| P/TBV Ratio | 14.40 | 2.31 |
| P/FCF Ratio | 16.00 | 17.44 |
| P/OCF Ratio | 15.50 | 13.32 |
Enterprise value
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| EV / Sales | 4.01 | 2.43 |
| EV / EBITDA | 17.03 | 14.69 |
| EV / EBIT | 17.03 | 18.47 |
| EV / FCF | 15.55 | 20.97 |
Income (trailing twelve months)
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Revenue | $3.37B | $57.94M |
| Gross Profit | $3.31B | $90.47M |
| Operating Income | $794.80M | -$21.44M |
| Pretax Income | $940.20M | -$14.45M |
| Net Income | $705.50M | -$22.46M |
| EBITDA | $794.80M | -$16.91M |
| EPS (Diluted) | $6.82 | -$0.83 |
Margins
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Gross Margin | 98.0% | 52.3% |
| Operating Margin | 23.6% | -44.5% |
| Pretax Margin | 27.9% | -13.0% |
| Profit Margin | 20.9% | -39.2% |
| EBITDA Margin | 23.6% | -31.3% |
| FCF Margin | 25.8% | -8.85% |
Returns
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | 22.1% | -53.1% |
| Return on Assets (ROA) | 15.3% | -41.0% |
| Return on Invested Capital (ROIC) | 23.7% | -32.0% |
| Return on Capital Employed (ROCE) | 17.7% | -37.8% |
Growth
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 34.4% | 6.01% |
| Net Income Growth (YoY) | 102.6% | -37.7% |
| EPS Growth (YoY) | 101.8% | -29.2% |
| FCF Growth (YoY) | 64.6% | 2.34% |
| Revenue Growth (3Y CAGR) | 24.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 22.3% | 6.42% |
| EPS Growth (3Y CAGR) | 44.1% | -0.17% |
| EPS Growth (5Y CAGR) | 2.34% | 3.77% |
Balance sheet
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $389.80M | $62.42M |
| Net Cash (Debt) | $389.80M | $15.68M |
| Net Cash Per Share | $3.83 | $0.66 |
| Equity (Book Value) | $3.69B | $48.79M |
| Book Value Per Share | $36.34 | $1.36 |
| Tangible Book Value | $967.00M | $23.06M |
| Working Capital | $763.00M | $75.77M |
Financial position
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Current Ratio | 1.87 | 3.30 |
| Quick Ratio | 1.46 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | $898.10M | -$12.35M |
| Capital Expenditures | -$27.70M | -$1.06M |
| Free Cash Flow | $870.40M | -$20.28M |
| FCF Per Share | $8.56 | -$0.42 |
Efficiency
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.73 | 0.38 |
| Inventory Turnover | 0.85 | 2.67 |
| Revenue Per Employee | $1.87M | $398.96K |
| Profits Per Employee | $391.94K | -$703.34K |
| Employee Count | 1,800 | 74 |
Dividends and yields
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Earnings Yield | 5.07% | -22.7% |
| FCF Yield | 6.25% | -9.07% |
| Buyback Yield | -0.90% | -0.73% |
| Shareholder Yield | -0.90% | 0.00% |
Shares
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 101,649,000 | 58,179,650 |
| Shares Change (YoY) | 0.85% | 11.1% |
| Shares Change (QoQ) | 0.99% | 0.54% |
| Float | 100,445,000 | 49,173,100 |
| Shares Held by Insiders | 1.18% | 11.6% |
| Shares Held by Institutions | 99.5% | 59.4% |
Taxes
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Income Tax | $234.70M | $91.50K |
| Effective Tax Rate | 25.0% | 20.6% |
Scores
| Measure | Neurocrine Biosciences | Industry median |
|---|---|---|
| Graham Number | $74.67 | $17.36 |
| Graham Upside | -45.5% | -43.6% |
| Altman Z-Score | 6.50 | -0.24 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Neurocrine Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.